{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:28:07Z","timestamp":1791224887586,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1124\/jpet.115.226969","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T22:09:20Z","timestamp":1441145360000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1"],"prefix":"10.1016","volume":"355","author":[{"given":"Sanjay K.","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thurman M.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeza","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam S.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Gattis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Swayze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Freier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Robert","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.226969_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/oli.1.1997.7.575","article-title":"Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats","volume":"7","author":"Agrawal","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1124\/jpet.115.226969_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.115.226969_bib3","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1172\/JCI5346","article-title":"DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model","volume":"103","author":"Berul","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.115.226969_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1009842114968","article-title":"Progressive atrioventricular conduction block in a mouse myotonic dystrophy model","volume":"4","author":"Berul","year":"2000","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1124\/jpet.115.226969_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.115.226969_bib6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1124\/jpet.115.226969_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.226969_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/nat.2013.0422","article-title":"Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys","volume":"23","author":"Burel","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.115.226969_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","article-title":"Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing","volume":"10","author":"Charlet-B","year":"2002","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.115.226969_bib10","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/cb3001606","article-title":"Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1","volume":"7","author":"Childs-Disney","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.115.226969_bib11","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","article-title":"Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts","volume":"94","author":"Davis","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/brain\/121.8.1557","article-title":"Age and causes of death in adult-onset myotonic dystrophy","volume":"121","author":"de Die-Smulders","year":"1998","journal-title":"Brain"},{"key":"10.1124\/jpet.115.226969_bib13","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1074\/jbc.M114.621607","article-title":"RNA toxicity and missplicing in the common eye disease fuchs endothelial corneal dystrophy","volume":"290","author":"Du","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.226969_bib14","doi-asserted-by":"crossref","first-page":"11866","DOI":"10.1073\/pnas.1018213108","article-title":"In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models","volume":"108","author":"Garc\u00eda-L\u00f3pez","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib15","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.226969_bib16","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne\u2019s muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.226969_bib17","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1056\/NEJMoa062800","article-title":"Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1","volume":"358","author":"Groh","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.226969_bib18","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1093\/nar\/gku275","article-title":"Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects","volume":"42","author":"Hoskins","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.115.226969_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.115.226969_bib20","doi-asserted-by":"crossref","first-page":"e1003043","DOI":"10.1371\/journal.pgen.1003043","article-title":"Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus","volume":"8","author":"Huguet","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.115.226969_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.115.226969_bib54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ng0796-316","article-title":"Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice","volume":"13","author":"Jansen","year":"1996","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.115.226969_bib22","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.115.226969_bib23","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1073\/pnas.1117019109","article-title":"RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12265-013-9495-7","article-title":"Antisense technology: an emerging platform for cardiovascular disease therapeutics","volume":"6","author":"Lee","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1124\/jpet.115.226969_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2012.0404","article-title":"Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy","volume":"23","author":"Leger","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/jpet.115.226969_bib26","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Reports"},{"key":"10.1124\/jpet.115.226969_bib27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.1062125","article-title":"Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9","volume":"293","author":"Liquori","year":"2001","journal-title":"Science"},{"key":"10.1124\/jpet.115.226969_bib28","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","article-title":"Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat","volume":"289","author":"Mankodi","year":"2000","journal-title":"Science"},{"key":"10.1124\/jpet.115.226969_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","article-title":"Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy","volume":"10","author":"Mankodi","year":"2002","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.115.226969_bib30","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","article-title":"Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy","volume":"19","author":"Miller","year":"2000","journal-title":"EMBO J"},{"key":"10.1124\/jpet.115.226969_bib31","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1073\/pnas.0505873102","article-title":"The structural basis of myotonic dystrophy from the crystal structure of CUG repeats","volume":"102","author":"Mooers","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib32","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.115.226969_bib33","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1073\/pnas.0905780106","article-title":"Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy","volume":"106","author":"Mulders","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib34","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1093\/nar\/gks298","article-title":"From dynamic combinatorial \u2018hit\u2019 to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy","volume":"40","author":"Ofori","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.115.226969_bib35","first-page":"622","article-title":"Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy","volume":"6","author":"Panaite","year":"2013","journal-title":"Dis Model Mech"},{"key":"10.1124\/jpet.115.226969_bib36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.280.5364.737","article-title":"Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy","volume":"280","author":"Philips","year":"1998","journal-title":"Science"},{"key":"10.1124\/jpet.115.226969_bib37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/jpet.115.226969_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ng0796-325","article-title":"Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy","volume":"13","author":"Reddy","year":"1996","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.115.226969_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.226969_bib40","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-11-0859","article-title":"Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","volume":"17","author":"Saad","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.115.226969_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.115.226969_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.226969_bib43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/hmg\/9.8.1185","article-title":"Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability","volume":"9","author":"Seznec","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.115.226969_bib44","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.115.226969_bib45","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.115.226969_bib46","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1073\/pnas.0903234106","article-title":"Pentamidine reverses the splicing defects associated with myotonic dystrophy","volume":"106","author":"Warf","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226969_bib47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.110.070409","article-title":"RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice","volume":"79","author":"Wei","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.115.226969_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12247-014-9183-4","article-title":"Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors","volume":"9","author":"Wen","year":"2014","journal-title":"J Pharm Innov"},{"key":"10.1124\/jpet.115.226969_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature11362","article-title":"Targeting nuclear RNA for in vivo correction of myotonic dystrophy","volume":"488","author":"Wheeler","year":"2012","journal-title":"Nature"},{"key":"10.1124\/jpet.115.226969_bib50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1173110","article-title":"Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA","volume":"325","author":"Wheeler","year":"2009","journal-title":"Science"},{"key":"10.1124\/jpet.115.226969_bib51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajpath.2012.04.006","article-title":"Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino","volume":"181","author":"Wu","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.115.226969_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.115.226969_bib53","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jconrel.2014.04.044","article-title":"Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics","volume":"193","author":"Zhou","year":"2014","journal-title":"J Control Release"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524191550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524191550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.226969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:37:01Z","timestamp":1739975821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524191550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0022356524191550"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.226969","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.226969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}